Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined
Findings from a large analysis of the GENIE Cohort v8.1
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Determination of the Incidence of Driver Mutations in Patients with NSCLC and Brain Metastases
Agents with CNS activity may have improved outcomes for patients with non-small cell lung cancer and brain metastases at diagnosis
Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from COVID-19-Associated Interstitial Pneumonia
A deep-learning algorithm can help to discriminate radiation pneumonitis from COVID-19 pneumonia
Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included in Clinical Trials
It is needed to understand if the cause of disparity is related to reduced access to supportive care or post-protocol therapy
Factors Associated with COVID-19 Severity Among Patients with Cancer
Findings from the COVID-19 and Cancer Consortium
FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
Evidence for efficacy is based on the results from the ZUMA-5 study
High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint Inhibitors Across All Cancer Types
Cancer types where TMB-H does not predict response generally show no relationship between tumour neoantigen load and CD8 T-cell infiltration
EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions for Infusion Continue to Outweigh Risks
Existing warning on ifosfamide-induced encephalopathy in the product information should be updated with the latest information on this side effect
Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell Lung Cancer
Results of an updated integrated analysis of the ALKA-372-001, STARTRK-1, and STARTRK-2
FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
Evidence for efficacy is based on the results from the TIVO-3 study
Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with AML or MDS
Clinical utility of whole-genome sequencing demonstrated for the genomic evaluation of patients with acute myeloid leukaemia or myelodysplastic syndromes
FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer
FDA also approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic for lorlatinib